Protocol: IL-23 blockade with guselkumab potentially modifies psoriasis pathogenesis: rationale and study protocol of a phase 3b, randomised, double-blind, multicentre study in participants with moderate-to-severe plaque-type psoriasis - Eyerich, K; Weisenseel, P; Pinter, A ((GUIDE) BMJ Open, 2021)